Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Australia secures distribution licence for animal nanofiber technology

Medical Australia secures distribution licence for animal nanofiber technology

Medical Australia (ASX:MLA) has secured an exclusive licensing agreement from Nanofiber Veterinary for distribution of NanoWhiskersV™ and NanoCareV™ product lines in Australia, Japan, and the United States.

The innovative product lines provide a valuable adjunct to MediVet’s already established adipose-derived stem cell technology to further enhance the treatment of a variety of degenerative conditions and diseases in animals including osteoarthritis.

The Nanofiber technology provides a supportive framework and an optimal healing environment for stem cells to proliferate, differentiate and regenerate damaged tissues.

NanoWhiskersV™ use injectable FDA-approved polymer fibres to increase cellular localisation in the area of ailment to regenerate joints.

It assists stem cell binding to the scaffolding matrix, and guides cellular growth causing cells to replicate and differentiate to form functional tissues.

NanoCareV™ provides expedited healing of all types of wounds in animals. It is a durable, bio-stable mesh with a temporary skin substitute that is placed directly over a wound followed by a series of Platelet Rich Plasma.

The technology from Nanofiber Solutions vastly increases the scope of application of MediVet’s Stem Cell Technology and for the treatment of wounds, joint injury and joint degeneration in both small animal and equine patients on a global scale providing a platform for growth.

MLA will now collaborate with Nanofiber Veterinary to continue ongoing research projects to achieve increased efficacy, continued learning and promote hands on access to veterinary regenerative medicine.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China

Register here to be notified of future MLA Company articles
View full MLA profile View Profile

Medical Australia Timeline

Related Articles

March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use